Making inroads in closing the gap in Indigenous health is at the heart of Gail Garvey’s research commitment.
Associate Professor Garvey was announced as the winner of the Bupa Health Foundation Emerging Health Researcher Award last night at the Research Australia Awards dinner. She will receive $25,000 to further her research to improve cancer treatment for Indigenous Australians.
“My research is focused on cancer and Aboriginal and Torres Strait Islander peoples, and I’m doing that because cancer has impacted on my family and my community and it’s an important issue that requires addressing,” said Assoc. Prof. Garvey.
“My research involves looking at Indigenous people’s participation in prevention strategies such as cancer screenings and investigating the support needs of Indigenous cancer patients and how that can impact on their uptake of services.”
Bupa Health Foundation Executive Leader, Annette Schmiede, said a record number of nominations were submitted this year.
“There were many outstanding researchers so choosing the finalists was rather a daunting task. Our finalists are a very special group and I congratulate each of them and look forward to watching their careers’ progress.
“Our 2016 Emerging Researcher Awards finalists have already made significant contributions that have been recognized at home and globally,” she said.
“Early career researchers often work in an uncertain environment and the Bupa Health Foundation’s funding helps to provide additional financial support.
“We want to keep encouraging our Australian researchers to think big and make breakthroughs that can improve the health of all Australians. Supporting and funding emerging researchers is vital to our research sector remaining a leader and globally competitive.” she said.
Along with the winner’s grant, the other four finalists were each awarded $5,000 to continue their research in clinical and translational science. Another five shortlisted researchers will receive $1000 to use towards their research career. (Full background on projects available below)
The Bupa Health Foundation is one of the country’s leading private charitable organisations dedicated to health. The Foundation has invested almost $30 million since its establishment in 2005 to support over 100 projects to improve the health and wellbeing of Australians.
The Bupa Health Foundation is listed on the Australian Competitive Grants Register. For more information, go to: www.bupa.com.au/foundation.
Details on research projects below
Bupa Health Foundation 2016 Emerging Health Researcher Award finalists
Associate Prof. Gail Garvey, Menzies School of Health Research - winner
Area of research: Improving cancer treatment for Aboriginal and Torres Strait Islander people
Nominator: Professor Joan Cunningham, Senior Principal Research Fellow, Menzies School of Health Research
Associate Prof. Gail Garvey is an Aboriginal research leader based in Brisbane whose research is committed to closing the gap through improvements in cancer treatment for Indigenous Australians. Her project aims to reduce deaths from cancer through earlier detection and appropriate treatment, as well as improving overall quality of life for Indigenous people with cancer by reducing their unmet needs. An emerging leader in this field, Associate Professor Garvey’s early achievements include pioneering a tool to assist with measuring the supportive care needs of Indigenous cancer patients which is now being used across Australia.
Dr Laura Dagley, The Walter and Eliza Hall Institute of Medical Research - finalist
Area of research: Innovating more accurate ways to identify acute rheumatic fever in Aboriginal children
Nominator: Dr. Andrew Webb, Laboratory Head, Proteomics, Systems Biology and Personalised Medicine Division at The Walter and Eliza Hall Institute of Medical Research
When acute rheumatic fever (ARF) is left untreated, it can lead to rheumatic heart disease (RHD), with disease-affected children often requiring multiple open-heart surgeries over their lifetime. ARF and RHD remains disproportionally high in Indigenous communities where Aboriginal people are nearly 20 times more likely to die from RHD than other Australians. This project aims to combat a clear need, with diagnosis of ARF changing little over the last 50 years. Dr Dagley has helped to innovate more accurate ways to identify ARF in Indigenous children. This new test identifies certain diagnostic markers circulating within the blood and will be available to clinics, therefore having the potential to reduce instances of RHD and its burden on Indigenous communities and our health system.
Dr Johana Paola Tello Velasquez, Eskitis Institute for Drug Discovery, Griffith University - finalist
Area of research: Preparation for a large-scale trial that aims to repair spinal cord injury following recent successful restoration of partial function in a human
Nominator: Dr James St John, Head of the Clem Jones Centre for Neurobiology and Stem Cell Research, Griffith University
Dr Johana Paola Tello Velasquez is an emerging innovator in neuroscience who is preparing for an upcoming trial that aims to repair spinal cord injuries; a devastating condition that currently has no effective treatment. With over 12,000 Australians currently living with spinal cord injury, the total economic cost in Australia is $2 billion annually. The upcoming trial follows recent exciting results – including successful restoration of partial function in a human – that indicate we are on the verge of a life-changing discovery. The trial will involve transplanting olfactory ensheathing cells taken from a patient’s nose into their injured spinal cord, to promote repair and regeneration. Dr Velasquez will provide intellectual input in preparation for the clinical trial as part of a large team of experts.
Dr Emily Reeve, Kolling Institute, Royal North Shore Hospital - finalist
Area of research: Guidelines to withdraw low-value medication for people with dementia
Nominator: Professor Sarah Hilmer, Head of Department of Clinical Pharmacology, University of Sydney
Dr Reeve’s research focuses on deprescribing (withdrawing) medications that are high risk or unnecessary, where the risks of taking the medicine(s) outweight the benefits. Deprescribing is a neglected and under-researched area, despite its impact in improving health outcomes and reducing financial costs from low-value health care. Dr Reeve’s current project will develop and implement deprescribing guidelines for people with dementia, which is important for our ageing population. She is already an emerging leader in this area, having developed the world’s first questionnaire to understand patients’ attitudes to deprescribing and developed this further to understand attitudes of carers of older people. It has been adopted across Australia, in Europe and in North America.
Dr Joseph Doyle, Department of Infectious Diseases, The Alfred - finalist
Area of research: Improving Hepatitis C treatment in highly vulnerable patients to ultimately eradicate the disease from society
Nominator: Professor Anton Peleg, Director, Department of Infectious Diseases, Alfred Health and Monash University
Dr Doyle’s research aims to improve hepatitis C treatment for vulnerable populations and ultimately eliminate it as a public health problem in Australia. His projects focus on delivering hepatitis C treatment to vulnerable people, with nearly 800 people so far receiving treatment. He has achieved this through innovative models of care, with a focus on greater support services in community settings. Dr Doyle shares his expertise as an advisor to the World Health Organisation and plays a significant role in the Elimination of Hepatitis C Partnership, which is among the first programs set up to eliminate viral hepatitis globally. Improved health of people with hepatitis C – and reduced transmission rates – using new oral combination treatments, indicate that it may be possible to eliminate hepatitis C.
Due to the high calibre of this year’s nominees, an additional ‘Commendation Award’ category has been included this year. Five nominees who were shortlisted but not selected as finalists will receive $1000 to use towards their research career:
For media enquiries or further information please contact: